spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Vaprisol 

 HSMN NewsFeed - 2 Dec 2019
Cumberland Pharmaceuticals Receives FDA Approval for RediTrex(TM) Product Line
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Sep 2018
Cumberland Pharmaceuticals Announces Senior Music Industry Executive Joins Its Board Of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Aug 2018
Cumberland Pharmaceuticals Appoints New Senior Executive
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Apr 2018
Cumberland Pharmaceuticals Expands into Oncology Support
Biopharmaceuticals Oncology Licensing Distribution
 HSMN NewsFeed - 25 Sep 2017
Cumberland Pharmaceuticals Launches Promotion of Totect(R) in The U.S. for Emergency Oncology Intervention
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 16 Jan 2017
Cumberland Pharmaceuticals Announces Kenneth J. Krogulski To Join Its Board Of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Nov 2016
Cumberland Pharmaceuticals Acquires U.S. Rights to Nordic Group's Methotrexate Injection Products
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 25 Jan 2016
Piramal Critical Care and Cumberland Pharmaceuticals Announce Launch of Caldolor and Vaprisol Co-Promotion
Biopharmaceuticals Distribution Product Launch
 HSMN NewsFeed - 1 Apr 2009
Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 22 Oct 2008
FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Oct 2007
Study Shows VAPRISOL(R) is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 10 Oct 2007
Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 20 Sep 2007
Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Biopharmaceuticals
 HSMN NewsFeed - 25 Mar 2007
EVEREST Data on Short- and Long-Term Use of Otsuka's Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACC's Late Breaking Clinical Trials
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 2 Mar 2007
FDA Approves Astellas' Vaprisol(R) for the Treatment of Hypervolemic Hyponatremia
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jun 2006
Adolor Corporation Appoints Scott T. Megaffin as Vice President, Marketing
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
Vaprisol
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.